Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer

Autor: Pralay Mukhopadyay, Jacek Jassem, Fernando Hurtado de Mendoza, Eva Thomas, Hyun Cheol Chung, Henri Roché, Valorie F. Chan, Rubi K. Li, Luis Fein, Xavier Pivot
Přispěvatelé: Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Service d'Oncologie Médicale [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), St. Luke's Medical Center, Kaiser Permanente, Yonsei Cancer Center, Centro de Oncologia Rosario, Veterans Memorial Medical Center, Medical University of Gdansk, Hospital Nacional Edgardo Rebagliati Martins, Bristol-Myers Squibb Company, Département d'oncologie médicale, Institut Claudius Regaud, Saas, Philippe, Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Institut National de la Santé et de la Recherche Médicale (INSERM)
Rok vydání: 2009
Předmět:
Cancer Research
Lung Neoplasms
Estrogen receptor
MESH: Epidemiologic Methods
Deoxycytidine
chemistry.chemical_compound
0302 clinical medicine
MESH: Liver Neoplasms
Antineoplastic Combined Chemotherapy Protocols
skin and connective tissue diseases
MESH: Treatment Outcome
MESH: Antimetabolites
Antineoplastic
0303 health sciences
Liver Neoplasms
Ixabepilone
Metastatic breast cancer
MESH: Drug Resistance
Neoplasm
3. Good health
ErbB Receptors
MESH: Antineoplastic Combined Chemotherapy Protocols
Treatment Outcome
Receptors
Estrogen
Oncology
030220 oncology & carcinogenesis
MESH: Receptors
Estrogen
[SDV.IMM]Life Sciences [q-bio]/Immunology
Female
Fluorouracil
Breast disease
Receptors
Progesterone
medicine.drug
MESH: Receptors
Progesterone
Antimetabolites
Antineoplastic
medicine.medical_specialty
[SDV.IMM] Life Sciences [q-bio]/Immunology
Antineoplastic Agents
Breast Neoplasms
MESH: Receptor
Epidermal Growth Factor
Biology
03 medical and health sciences
Breast cancer
Internal medicine
Progesterone receptor
Biomarkers
Tumor
medicine
Humans
MESH: Epothilones
Capecitabine
030304 developmental biology
MESH: Humans
MESH: Deoxycytidine
Cancer
medicine.disease
MESH: Lung Neoplasms
Endocrinology
chemistry
Drug Resistance
Neoplasm
Epothilones
MESH: Tumor Markers
Biological
Cancer research
MESH: Antineoplastic Agents
Epidemiologic Methods
MESH: Female
MESH: Fluorouracil
MESH: Breast Neoplasms
Tamoxifen
Zdroj: European Journal of Cancer
European Journal of Cancer, Elsevier, 2009, 45 (17), pp.2940-6. ⟨10.1016/j.ejca.2009.07.015⟩
ISSN: 0959-8049
Popis: International audience; Oestrogen receptor (ER)-negative breast cancer, including oestrogen receptor-, progesterone receptor- and human epidermal growth factor receptor 2-negative (ER/PR/HER2-negative) breast cancer, is more aggressive than ER-positive disease. A major limitation in the treatment of ER-negative disease subtypes is the inherent insensitivity to hormonal agents (tamoxifen, aromatase inhibitors) that are widely used in the treatment of breast cancer. Thus, therapeutic options for poor prognosis patients with ER-negative breast cancer are limited to a handful of chemotherapeutic agents, and new agents are needed to improve the treatment of this disease. Ixabepilone, a novel epothilone B analogue with low susceptibility to cellular mechanisms that confer resistance to taxanes and other chemotherapeutic agents, has demonstrated potent preclinical antitumour activity in multiple models, including those with primary or acquired drug resistance. This review summarises the results of a prospective subset analysis from a phase III clinical trial evaluating ixabepilone for the treatment of metastatic breast cancer (MBC), in which efficacy and safety were evaluated in patients with ER-negative and ER/PR/HER2-negative disease.
Databáze: OpenAIRE
Externí odkaz: